Testing effectiveness (Phase 2)Study completedNCT02443883
What this trial is testing
Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Eli Lilly and Company 164